Sunil Healthcare manufactures empty hard gelatin and HPMC capsule shells for the pharmaceutical and dietary supplement industries. The company operates a manufacturing facility in Rajasthan and sells its products to drug formulators both in India and across global markets.
The company operates in a commoditized segment of the pharmaceutical supply chain where it lacks significant scale or proprietary technology to command pricing power. Financial metrics contradict any moat claim, as evidenced by a low average net margin of 1.3% and an average ROE of 3.3%, which are well below the cost of capital.
Capital has been deployed into capacity expansions from 13 billion to 15 billion units, yet these investments have coincided with declining revenues and poor returns on equity. The company maintains a high debt-to-equity ratio of 0.80 while interest coverage is precariously low at 1.36, suggesting inefficient use of borrowed funds.
The company's demise was driven by a lethal combination of capital misallocation and operational fragility. Despite expanding capacity to 15 billion units, revenue continued its downward trajectory, proving that building more of a commodity nobody wants at a premium price is a fool's errand. The razor-thin interest coverage eventually buckled under rising rates, while the board continued to prioritize family remuneration and luxury vehicle loans over debt reduction. As margins remained trapped below the cost of capital, the equity was slowly cannibalized by interest obligations and related-party leakages, leaving shareholders with a hollowed-out shell of a manufacturing business.
RichFakir rates Sunil Healthcare Ltd's business quality as poor — 20/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sunil Healthcare Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sunil Healthcare Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sunil Healthcare Ltd's fair value is about ₹18 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →